Biotechnology Assets, S.A.

BST

ES0184980003

Biotechnology & Medical Research

Delayed BME Other stock markets 10:19:39 2024-05-09 am EDT			5-day change	1st Jan Change
0.332 ^EUR	-0.60%		+1.22%	-16.16%

Apr. 05	Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt	CI

ADL Bionatur Solutions, S.A. Provides Sales Guidance for 2019

May 06, 2019 at 07:34 am EDT

ADL Bionatur Solutions provided expected sales result for 2019. The Company expected to generate revenues in the range of EUR 50 million to EUR 55 million, again doubling the company's turnover.

Latest news about Biotechnology Assets, S.A.

Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt	23-04-10	CI
Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-10	CI
Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt	22-04-12	CI
Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-12	CI
ADL Bionatur Solutions, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-10-29	CI
ADL Bionatur Solutions, S.A. announced that it has received ?12 million in funding from Kartesia Advisor LLP	21-10-19	CI
Adl Bionatur Solutions, S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-05-11	CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt	21-05-10	CI
ADL Bionatur Solutions, S.A. announced that it expects to receive €5 million in funding	21-03-18	CI
ADL Bionatur Solutions, S.A. announced that it has received €12 million in funding from Kartesia Advisor LLP	21-02-25	CI
Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. and Black Toro Capital LLP.	20-10-06	CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt	20-06-21	CI
ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million	19-12-02	CI
ADL Bionatur Solutions Announces Revenue Results for the Third Quarter and Nine Months of 2019; Confirms Revenue Guidance for the Full Year of 2019	19-11-13	CI
ADL Bionatur Solutions Announces Earnings Results for the First Six Months of 2019; Provides Guidance for the Full Year 2019	19-10-10	CI
ADL Bionatur Solutions, S.A. announced that it has received €25 million in funding from Kartesia Advisor LLP	19-08-11	CI
ADL Bionatur Solutions, S.A. Provides Sales Guidance for 2019	19-08-07	CI
ADL Bionatur Solutions Enters into an Initial EUR 13 Million Strategic Alliance with Japanese Pharma Company	19-08-07	CI
ADL Bionatur Solutions and Amyris, Inc. Expand Contract to 2020	19-07-22	CI
ADL Bionatur Solutions Increases 2019 Production for Global Nutrition Company for Additional Revenues of over EUR 2.5 Million	19-07-09	CI
ADL Bionatur Solutions, S.A. Provides Sales Guidance for 2019	19-05-06	CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt	19-04-11	CI
Nutricion Center NC and ADL Bionatur Solutions Sign Strategic Alliance to Tackle Weight Control by Rebalancing the Gut Microbiome	19-02-19	CI
Amyris and ADL Bionatur Solutions Expand Production Agreement to Meet Growing Demand	18-12-10	CI

Chart Biotechnology Assets, S.A.

Duration

Period

More charts

Biotechnology Assets SA, formerly known as ADL Bionatur Solutions SA, is a Spain-based biotech company. The Firmâs main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company, through its subsidiaries, is also present in Luxembourg, Hong Kong and USA.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOTECHNOLOGY ASSETS, S.A.	-16.16%	20.72M
VERTEX PHARMACEUTICALS INCORPORATED	+2.52%	108B
REGENERON PHARMACEUTICALS, INC.	+9.78%	105B
ARGENX SE	+0.70%	23.46B
BIONTECH SE	-12.48%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-7.47%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+6.22%	13.99B
SAREPTA THERAPEUTICS, INC.	+35.07%	12.53B

Bio Therapeutic Drugs

Biotechnology Assets, S.A.

Equities

BST

ES0184980003

Biotechnology & Medical Research

ADL Bionatur Solutions, S.A. Provides Sales Guidance for 2019

Latest news about Biotechnology Assets, S.A.

Chart Biotechnology Assets, S.A.

Company Profile

Income Statement Evolution

Sector Bio Therapeutic Drugs